Plasma Presepsin as a Diagnostic Marker for Early-Onset Sepsis in Newborns
This prospective cohort study demonstrates that plasma presepsin is a superior diagnostic biomarker for neonatal early-onset sepsis compared to conventional markers, with optimal thresholds identified for both umbilical cord and peripheral blood samples that ensure high accuracy and a reliable window for timely clinical intervention.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every newborn enters the world with a fragile immune system, a defense network that is still learning how to fight. For some, this vulnerability is exploited by bacteria that slip into the bloodstream before or during birth, causing a condition known as early-onset sepsis. This infection can strike with terrifying speed, leading to shock and organ failure within hours. The medical challenge has always been a race against time: doctors need to know immediately if a baby is sick with an infection, but the standard test, which involves growing bacteria in a lab, takes days to return a result. Waiting that long is too risky, so doctors often rely on other clues, like general blood counts or proteins that rise during inflammation. However, these clues are often vague, rising for reasons other than infection, which leads to a difficult choice: treat every baby with antibiotics just in case, or risk missing a true infection. Finding a marker that is both fast and precise has been a long-standing goal in neonatal care.
A team of researchers at Peking University Shenzhen Hospital recently set out to test a new tool called presepsin to see if it could solve this problem. They focused on a specific protein that the body releases when it detects an invader, one that appears in the blood very quickly after an infection starts. The researchers gathered data from 355 newborns who were at risk for infection due to factors like a mother's fever or a long time between water breaking and birth. They collected blood samples from these infants in two ways: from the umbilical cord immediately after delivery and from the baby's arm or leg within the first three days of life. They then measured the levels of presepsin alongside older, more traditional markers like C-reactive protein and procalcitonin to see which one told the clearest story.
The results painted a clear picture of presepsin's potential. When the researchers looked at the blood from babies who were actually infected, they found that the levels of this new protein were significantly higher than in healthy babies. The test was remarkably good at distinguishing between the two groups. For blood drawn from the umbilical cord, the researchers identified a specific level, 762.96 picograms per milliliter, as the best point to separate sick infants from healthy ones. At this threshold, the test correctly identified 94 percent of the infected babies, catching almost every case. For blood drawn from the baby's body after birth, the best threshold was slightly lower at 752.7 picograms per milliliter. While this version caught slightly fewer infected babies, it was much better at confirming that a baby was healthy, correctly ruling out infection in 95.6 percent of non-infected cases. In direct comparisons, this new marker outperformed the traditional tests, which often gave confusing results because they could rise due to stress or normal birth processes rather than infection.
One of the most useful discoveries was how stable this marker remained over time. In healthy babies, the level of presepsin stayed steady for at least 72 hours after birth, showing no wild swings that would make the test hard to interpret. In babies who were infected, the levels remained high and steady for at least the first 24 hours. This stability is crucial because it means doctors do not have to worry about the exact minute they draw the blood; the result will be reliable whether the sample is taken an hour after birth or two days later. The study also noted that blood from the umbilical cord consistently showed higher levels of the protein than blood from the baby's body, suggesting that the cord blood might be the best place to look for an immediate signal right at birth.
The researchers concluded that presepsin offers a powerful way to diagnose early-onset sepsis, providing a level of accuracy that older methods cannot match. By using the umbilical cord blood for an initial screen and the peripheral blood for confirmation, doctors could potentially make faster, more confident decisions about treatment. This approach could spare many healthy newborns from unnecessary antibiotics while ensuring that those who are truly sick receive life-saving care immediately. While the study was limited by the fact that only a small number of babies had infections confirmed by bacterial culture, the sheer size of the group studied and the consistency of the results suggest that this marker is a significant step forward. It offers a clearer window into the newborn's immune state, turning a period of uncertainty into a moment of precise medical understanding.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.